KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Enterprise Value (2016 - 2025)

Travere Therapeutics' Enterprise Value history spans 13 years, with the latest figure at -$93.0 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 58.94% year-over-year to -$93.0 million; the TTM value through Dec 2025 reached -$93.0 million, down 58.94%, while the annual FY2025 figure was -$93.0 million, 58.94% down from the prior year.
  • Enterprise Value reached -$93.0 million in Q4 2025 per TVTX's latest filing, up from -$110.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$32.3 million in Q2 2024 to a low of -$256.6 million in Q1 2022.
  • Average Enterprise Value over 5 years is -$107.2 million, with a median of -$88.2 million recorded in 2021.
  • Peak YoY movement for Enterprise Value: skyrocketed 74.76% in 2024, then crashed 204.68% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$165.8 million in 2021, then soared by 62.78% to -$61.7 million in 2022, then rose by 5.69% to -$58.2 million in 2023, then fell by 0.62% to -$58.5 million in 2024, then tumbled by 58.94% to -$93.0 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Enterprise Value are -$93.0 million (Q4 2025), -$110.9 million (Q3 2025), and -$75.2 million (Q2 2025).